Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The term **cyclophosphamide or azathioprine** refers to two distinct immunosuppressive agents frequently utilized as alternatives or in sequence for the management of severe autoimmune and inflammatory conditions. **Cyclophosphamide** is a nitrogen mustard alkylating agent that functions by attaching alkyl groups to DNA, leading to intra-strand and inter-strand cross-linking which triggers apoptosis, particularly in rapidly proliferating lymphocytes. **Azathioprine** is a purine antimetabolite and a prodrug of 6-mercaptopurine; it exerts its effect by inhibiting de novo purine synthesis and by being incorporated into DNA and RNA, thereby disrupting nucleic acid synthesis and inhibiting T and B cell proliferation. In clinical practice, cyclophosphamide is often employed for induction therapy in life-threatening diseases like lupus nephritis or systemic vasculitis due to its potent but toxic nature, while azathioprine is commonly used for long-term maintenance therapy to prevent disease relapse.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide or azathioprine.